Vinzerex subcutaneous injection 160 mg autoinjector

Vinzerex subcutaneous injection 160 mg autoinjector, manufactured by UCB Japan, contains bimekizumab (genetical recombination). Bimekizumab is a humanized monoclonal antibody that selectively inhibits both interleukin-17A (IL-17A) and interleukin-17F (IL-17F), which are key cytokines involved in inflammation. It is used to treat moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and hidradenitis suppura…